Overview Latest Regional Industry Featured Multimedia Other Languages Public Company News
All APAC Global
All APAC Global
All APAC Global
All APAC Global
FDA Advisory Committee Votes to Recommend Additional Data for Sintilimab Submission 2022-02-11 10:44
Innovent Announces the Approval of Pemazyre® (pemigatinib) in Hong Kong Market for the Treatment of Adults With Locally Advanced Or Metastatic Cholangiocarcinoma With A FGFR2 Fusion Or Rearrangement That Have Progressed After At Least One Prior Line Of Systemic Therapy 2022-01-24 15:22
Innovent and Eli Lilly and Company Announced Final Clinical Results and Biomarker Analysis of Phase Ib Study of TYVYT® (Sintilimab Injection) Plus Bevacizumab Biosimilar Injection for Advanced Hepatocellular Carcinoma at ASCO GI Annual Meeting 2022 2022-01-22 08:00
Sana Biotechnology, IASO Biotherapeutics, and Innovent Biologics Announce Non-Exclusive License Agreement for Clinically Validated BCMA CAR Construct 2022-01-11 05:30
Innovent Announces NMPA of China Acceptance of a Supplemental New Drug Application for TYVYT® (Sintilimab Injection plus Bevacizumab Biosimilar Injection and Chemotherapy in Patients with EGFR-mutated Non-squamous Non-small Cell Lung Cancer who Progressed after EGFR-TKI Therapy 2021-12-24 16:51
Innovent Announces Pivotal Phase 2 Results for Parsaclisib (PI3Kδ inhibitor) Presented at ASH 2021 Show Durable Responses in Patients with Relapsed or Refractory Follicular Lymphoma 2021-12-14 08:00
Innovent and IASO Announced Updated Clinical Data of BCMA CAR-T Therapy in Oral Presentation at 2021 ASH Annual Meeting 2021-12-13 08:00
Innovent Releases Results of a Phase 1 Clinical Study of IBI362, a Dual Glucagon-like Peptide-1 and Glucagon Receptor Agonist in Chinese Patients with Type 2 Diabetes at the International Diabetes Federation Congress 2021 2021-12-07 08:00
Innovent and Lilly Announce Successful Expansion of Sintilimab in China National Reimbursement Drug List to Include Three Additional First-Line Indications 2021-12-03 12:37
Innovent Biologics and Ascentage Pharma Announce the China NMPA Approval for China's First Third-Generation BCR-ABL Inhibitor Olverembatinib for the Treatment of Chronic Myeloid Leukemia 2021-12-01 08:00
Innovent Releases the ORIENT-31 Phase 3 Study First Interim Analysis Results of Sintilimab plus BYVASDA (bevacizumab biosimilar injection) and Chemotherapy in Patients with EGFR-mutated Nonsquamous Non-small Cell Lung Cancer who Progressed After EGFR-TKI Therapy at ESMO Virtual Plenary 2021 2021-11-22 08:16
Innovent Announces Inclusion of the Company's Stock (01801.HK) in the Hang Seng China Enterprises Index 2021-11-22 08:00
Innovent Announces the Results of the Phase Ib Clinical Trial of IBI302, a First-in-class Anti-VEGF and Anti-Complement Bi-specific Fusion Protein for Neovascular Age-Related Macular Degeneration at 2021 American Academy of Ophthalmology 2021-11-15 08:00
Innovent Publishes the Preclinical Results of IBI319 (Anti PD-1/CD137 Bispecific Antibody) in Nature Communications 2021-11-08 08:00
Innovent Announces NMPA Acceptance of a Supplemental New Drug Application for Sintilimab in Combination with Chemotherapy as First-Line Treatment for Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma 2021-11-04 17:00
Innovent and NeoCura Announce Strategic Collaboration to Study the Combination Therapy of Sintilimab and Neoantigen Vaccine NEO_PLIN2101 for Cancer Treatment in China 2021-10-28 08:00
Innovent Announces ORIENT-31, a Phase 3 Study of Sintilimab in Patients with EGFR-Mutated Nonsquamous Non-Small Cell Lung Cancer with Prior EGFR-TKI Treatment, Has Met Primary Endpoint 2021-10-18 08:00
Innovent Announces the First Patient Dosed in the Phase I/II Study of IBI351 (KRAS G12C inhibitor) in Patients with Advanced Malignant Tumors 2021-09-30 08:00
Innovent Releases Preliminary Results of the Phase Ia Dose-Escalation study of IBI315 (Anti-Her2/PD-1 Bispecific Antibody) in Patients with Advanced Solid Tumors at CSCO Annual Meeting 2021 2021-09-29 08:00
Innovent and UNION Therapeutics Enter into Strategic Collaboration and License Agreement for Orismilast, a Next-generation PDE4 Inhibitor for Inflammatory Dermatology Conditions 2021-09-28 08:00
1 7 8 9 10 11 17